DK1444261T3 - Immunogene ALK (anaplastisk lymfomakinase) peptider - Google Patents

Immunogene ALK (anaplastisk lymfomakinase) peptider

Info

Publication number
DK1444261T3
DK1444261T3 DK02787687T DK02787687T DK1444261T3 DK 1444261 T3 DK1444261 T3 DK 1444261T3 DK 02787687 T DK02787687 T DK 02787687T DK 02787687 T DK02787687 T DK 02787687T DK 1444261 T3 DK1444261 T3 DK 1444261T3
Authority
DK
Denmark
Prior art keywords
alk
peptides
anaplastic lymphoma
lymphoma kinase
immunogenic
Prior art date
Application number
DK02787687T
Other languages
English (en)
Inventor
Carlo Gambacorti-Passerini
Lorena Passoni
Original Assignee
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Naz Stud Cura Dei Tumori filed Critical Ist Naz Stud Cura Dei Tumori
Application granted granted Critical
Publication of DK1444261T3 publication Critical patent/DK1444261T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464454Enzymes
    • A61K39/464462Kinases, e.g. Raf or Src
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48Blood cells, e.g. leukemia or lymphoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02787687T 2001-11-15 2002-11-14 Immunogene ALK (anaplastisk lymfomakinase) peptider DK1444261T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/008,377 US20030157101A1 (en) 2001-11-15 2001-11-15 Immunogenic ALK peptides

Publications (1)

Publication Number Publication Date
DK1444261T3 true DK1444261T3 (da) 2006-03-20

Family

ID=21731292

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02787687T DK1444261T3 (da) 2001-11-15 2002-11-14 Immunogene ALK (anaplastisk lymfomakinase) peptider

Country Status (9)

Country Link
US (1) US20030157101A1 (da)
EP (1) EP1444261B1 (da)
AT (1) ATE308565T1 (da)
AU (1) AU2002352011A1 (da)
CY (1) CY1105357T1 (da)
DE (1) DE60207103T2 (da)
DK (1) DK1444261T3 (da)
ES (1) ES2250727T3 (da)
WO (1) WO2003042243A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1855707E (pt) 2005-02-28 2012-05-25 Oncotherapy Science Inc Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos
EP2042191B1 (en) 2007-09-28 2013-01-02 Roberto Chiarle Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination
CA3012764A1 (en) 2016-01-29 2017-08-03 Vedantra Pharmaceuticals, Inc. Alk polypeptides and methods of use thereof
AU2020351168A1 (en) * 2019-09-18 2022-04-14 Children's Medical Center Corporation An anaplastic lymphoma kinase (ALK) cancer vaccine and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma

Also Published As

Publication number Publication date
WO2003042243A2 (en) 2003-05-22
AU2002352011A1 (en) 2003-05-26
DE60207103T2 (de) 2006-10-05
EP1444261A2 (en) 2004-08-11
EP1444261B1 (en) 2005-11-02
ATE308565T1 (de) 2005-11-15
DE60207103D1 (en) 2005-12-08
CY1105357T1 (el) 2010-03-03
ES2250727T3 (es) 2006-04-16
WO2003042243A3 (en) 2004-03-25
US20030157101A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
MXPA05008128A (es) Peptidos derivados de survivina y uso de los mismos.
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
HK1068886A1 (en) Indolinone derivatives useful as protein kinase inhibitors
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
AU2002359727A1 (en) Fused cyclic modulators of nuclear hormone receptor function
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
UA85365C2 (ru) Продукт конъюгирования цитокина для использования в противораковой терапии
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
AU2003267401A1 (en) Novel mhc ii associated peptides
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider
WO2003093298A3 (en) Immunogenic peptides
WO2003104263A3 (en) CYTOKINES AND CYTOKINE RECEPTORS WITH REDUCED IMMUNOGENECITY
NO20061542L (no) P185neu-Kodende DNA samt terapeutiske anvendelser derav
DK0996636T3 (da) HA-1-antigenet
ATE431742T1 (de) Modifizierte zytokine für krebs therapie
UY26170A1 (es) Antigeno (c42) asociados a tumores
MXPA03005031A (es) Composicion vacunal que contiene factor de crecimiento transformante alfa.